Charles River Labs faces a 60% loss due to reduced R&D spending, FDA's phase-out of animal testing, and increased competition. Learn more on CRL stock here.

Below is Validea's guru fundamental report for CHARLES RIVER LBRTRS NTRNTL INC (CRL). Of the 22 guru strategies we follow, CRL rates highest using our Shareholder Yield Investor model based on the ...

Over the last six months, Charles River Laboratories’s shares have sunk to $173.44, producing a disappointing 15.7% loss while the S&P 500 was flat. This might have investors contemplating their ...

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.

Charles River Laboratories International, Inc. (NYSE:CRL) is not on our list of 30 Most Popular Stocks Among Hedge Funds.As per our database, 40 hedge fund portfolios held Charles River ...

Despite an initial PDUFA date of August 22, 2024, the CRL for linvoseltamab was anticipated based on Regeneron’s Q2 earnings call at the beginning of August. 3 “The FDA has not informed us of ...